Stevens Capital Management LP reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 82.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,077 shares of the company’s stock after selling 38,891 shares during the quarter. Stevens Capital Management LP’s holdings in IDEXX Laboratories were worth $1,256,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. BlackRock Inc. lifted its holdings in IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock worth $1,146,142,000 after acquiring an additional 673,347 shares during the period. Advisors Capital Management LLC bought a new stake in IDEXX Laboratories during the third quarter worth $262,000. Cipher Capital LP bought a new stake in IDEXX Laboratories during the second quarter worth $2,284,000. Pitcairn Co. lifted its holdings in IDEXX Laboratories by 21.8% during the second quarter. Pitcairn Co. now owns 6,977 shares of the company’s stock worth $1,126,000 after acquiring an additional 1,249 shares during the period. Finally, American Century Companies Inc. lifted its holdings in IDEXX Laboratories by 131.7% during the second quarter. American Century Companies Inc. now owns 480,978 shares of the company’s stock worth $77,639,000 after acquiring an additional 273,398 shares during the period. Institutional investors and hedge funds own 88.03% of the company’s stock.
A number of analysts have issued reports on the company. Canaccord Genuity reissued a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research report on Friday, October 6th. Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price for the company in a research report on Wednesday, August 23rd. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research report on Wednesday, August 2nd. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 target price for the company in a research report on Wednesday, July 19th. Finally, CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price for the company in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $173.67.
In other news, Chairman Jonathan W. Ayers sold 58,000 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $155.00, for a total value of $8,990,000.00. Following the completion of the transaction, the chairman now directly owns 1,043,034 shares in the company, valued at $161,670,270. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Rebecca M. Henderson sold 2,578 shares of IDEXX Laboratories stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $152.86, for a total value of $394,073.08. Following the completion of the transaction, the director now owns 17,274 shares of the company’s stock, valued at $2,640,503.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 150,734 shares of company stock valued at $23,073,486. 2.77% of the stock is owned by company insiders.
Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $147.79 on Tuesday. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77. IDEXX Laboratories, Inc. has a 52-week low of $108.99 and a 52-week high of $173.01. The stock has a market capitalization of $12,880.46, a price-to-earnings ratio of 49.72, a price-to-earnings-growth ratio of 2.23 and a beta of 0.46.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. The business had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the business posted $0.62 earnings per share. equities analysts predict that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.